Skip to NavigationSkip to content


Vaccine company Acambis has joined rivals PowderJect and Celltech in the elite group of profitable UK biotech companies.
Matthew Emmens, former head of Merck KGaA's global prescription group, has been appointed as the new Chief Executive of Shire Pharmaceuticals.
Plans to make clinical trials mandatory for all drugs intended for children are progressing in the US.
GlaxoSmithKline has increased its predicted earnings for 2003 despite a virtually unchanged turnover in the second quarter.
Pfizer has pulled out of its partnership with UK biotech company Phytopharm to develop an obesity treatment based on a cactus plant.
A further 38 hospital have been invited to apply for foundation trust status after winning three stars in the recent NHS performance ratings.
Aventis may struggle to replace revenue from its ageing blockbusters despite a strong performance in the second quarter, according to analysts.
Strong sales of established and new products in the second quarter saw both Bristol-Myers Squibb and Eli Lilly beat analysts' earning forecasts.
Growth in new products are helping to plug the sizeable gap left by three of AstraZeneca's ageing blockbusters Prilosec (Losec), Zestril and Nolvadex.
The weakness of the US dollar more than halved Sanofi-Synthelabo's earnings in the first half of this year, but disguised strong underlying growth...
Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches